Identification
NameSulpiride
Accession NumberDB00391  (APRD00032)
TypeSmall Molecule
GroupsApproved
Description

A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
(+-)-Sulpiride
5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide
Levosulpirida
Levosulpiride
Levosulpiridum
N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide
N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-O-anisamide
Sulpirid
Sulpirida
Sulpiridum
Sulpyrid
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BosnylNot Available
DogmatilNot Available
DogmatylNot Available
DolmatilNot Available
EglonylNot Available
EspirideNot Available
MeresaNot Available
ModalNot Available
Brand mixturesNot Available
Categories
UNII7MNE9M8287
CAS number15676-16-1
WeightAverage: 341.426
Monoisotopic: 341.140926929
Chemical FormulaC15H23N3O4S
InChI KeyBGRJTUBHPOOWDU-UHFFFAOYSA-N
InChI
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
IUPAC Name
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
SMILES
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
Pharmacology
Indication

Sulpiride is indicated for the treatment of schizophrenia.

Structured Indications Not Available
Pharmacodynamics

Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.

Mechanism of action

In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.

TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
Carbonic anhydrase 2Proteinunknown
inhibitor
HumanP00918 details
Carbonic anhydrase 3Proteinunknown
inhibitor
HumanP07451 details
Related Articles
Absorption

Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.

Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life

6 to 8 hours

ClearanceNot Available
Toxicity

Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineSulpiride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3-Hydroxyhippuric acidThe risk or severity of adverse effects can be increased when 3-Hydroxyhippuric acid is combined with Sulpiride.Experimental
3,4-MethylenedioxyamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSulpiride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sulpiride is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sulpiride.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sulpiride.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Sulpiride.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Acetyldigitoxin.Approved
AclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sage 547.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alprazolam.Approved, Illicit, Investigational
Aluminum hydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.Approved
Aminohippuric acidThe risk or severity of adverse effects can be increased when Aminohippuric acid is combined with Sulpiride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sulpiride.Experimental
AmphetamineSulpiride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Anisotropine MethylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Anisotropine Methylbromide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Sulpiride.Approved
Atracurium besylateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Atropine.Approved, Vet Approved
AzelastineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Sulpiride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.Illicit
BenactyzineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benactyzine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sulpiride.Approved
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Sulpiride.Investigational
BenzatropineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benzatropine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzocaine.Approved
BenzphetamineSulpiride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzyl alcohol.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Sulpiride.Investigational
BiperidenThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Sulpiride can be decreased when it is combined with Bismuth Subcitrate.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sulpiride.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved, Investigational
BromoprideThe risk or severity of adverse effects can be increased when Bromopride is combined with Sulpiride.Approved
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Sulpiride.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.Approved, Investigational
BuprenorphineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butalbital.Approved, Illicit
ButethalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cabergoline.Approved
Calcium CarbonateThe serum concentration of Sulpiride can be decreased when it is combined with Calcium carbonate.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Sulpiride.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorphenamine.Approved
ChlorphenoxamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Chlorphenoxamine.Withdrawn
ChlorphentermineSulpiride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.Approved, Vet Approved
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Sulpiride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Sulpiride.Approved
ClemastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clobazam.Approved, Illicit
ClomipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sulpiride.Approved
CocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.Approved, Illicit
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Sulpiride.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyclobenzaprine.Approved
CyclopentolateThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclopentolate.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Darifenacin.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desipramine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.Approved
DesloratadineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Sulpiride.Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexbrompheniramine.Approved
DexetimideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineSulpiride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.Approved
DiethylpropionSulpiride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Difenoxin.Approved, Illicit
DigitoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diphenoxylate.Approved, Illicit
DoxepinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Illicit
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.Approved
DyclonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sulpiride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pregnanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sulpiride.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sulpiride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sulpiride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved
EthanolSulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride.Approved, Illicit, Withdrawn
EthopropazineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ethopropazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sulpiride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulpiride.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sulpiride.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sulpiride.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Sulpiride is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Heroin.Approved, Illicit
HexamethoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved, Vet Approved
HydrocodoneSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.Approved, Illicit
HydroxyamphetamineSulpiride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
HyoscyamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hyoscyamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sulpiride.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.Approved
ImipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sulpiride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sulpiride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulpiride.Approved, Investigational
LisdexamfetamineSulpiride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Sulpiride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sulpiride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Sulpiride.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.Approved
MagaldrateThe serum concentration of Sulpiride can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium HydroxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium oxide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Maprotiline.Approved
MecamylamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Meclizine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Sulpiride is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Sulpiride.Approved
MephedroneSulpiride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineSulpiride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.Approved, Illicit
MequitazineSulpiride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sulpiride.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineSulpiride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methantheline.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methaqualone.Illicit, Withdrawn
MethenamineThe risk or severity of adverse effects can be increased when Hexamethylenetetramine is combined with Sulpiride.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sulpiride.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Sulpiride is combined with ECGONINE METHYL ESTER.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenobarbital.Approved
MetixeneThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Metixene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.Approved
MetyrosineSulpiride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Sulpiride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
MirtazapineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDASulpiride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Sulpiride.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Anvirzel.Experimental
OlopatadineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sulpiride.Approved
OpiumThe risk or severity of adverse effects can be increased when Sulpiride is combined with Opium.Approved, Illicit
OrphenadrineSulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.Investigational
OuabainThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxybuprocaine.Approved
OxybutyninThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxyphenonium.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.Approved
PancuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pancuronium.Approved
ParaldehydeSulpiride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Sulpiride.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Sulpiride.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.Approved
PethidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sulpiride.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenobarbital.Approved
PhentermineSulpiride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sulpiride.Approved
PipecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sulpiride.Approved
PirenzepineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pirenzepine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Piritramide.Investigational
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Sulpiride.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.Approved
PramipexoleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sulpiride.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.Approved
ProcaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Procyclidine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Promethazine.Approved
PropanthelineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propantheline.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Sulpiride.Approved
PropiverineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Sulpiride.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Protriptyline.Approved
PseudoephedrineSulpiride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.Approved
QuinagolideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinagolide.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.Approved
QuinidineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Quinidine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Sulpiride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sulpiride.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Sulpiride.Investigational
RitobegronSulpiride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sulpiride.Approved
RopiniroleThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride.Approved
RotigotineSulpiride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sulpiride.Approved
ScopolamineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sulpiride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Sulpiride.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Sulpiride.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SolifenacinThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Solifenacin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Sulpiride is combined with Stiripentol.Approved
SucralfateThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sulpiride.Approved, Investigational
SuvorexantSulpiride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetrodotoxin.Investigational
ThalidomideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Sulpiride.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Sulpiride.Approved, Investigational
TiotropiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tolcapone.Approved, Withdrawn
TolterodineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Sulpiride is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trihexyphenidyl.Approved
TrimethaphanThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Triprolidine.Approved
TropicamideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tropicamide.Approved
TrospiumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trospium.Approved
TubocurarineThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tubocurarine.Approved
UmeclidiniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sulpiride.Approved, Investigational
VecuroniumThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Sulpiride.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Sulpiride.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sulpiride.Approved, Investigational
ZolpidemSulpiride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Sulpiride.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AL07 — LevosulpirideN05AL01 — Sulpiride
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceIndigestion1
2, 3CompletedTreatmentAcute Agitation1
3RecruitingTreatmentAnxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)178 dec °CPhysProp
water solubility2280 mg/LNot Available
logP0.57HOEGBERG,T ET AL. 1986
Caco2 permeability-6.16ADME Research, USCD
pKa9.12EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.537 mg/mLALOGPS
logP1.2ALOGPS
logP0.22ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)10.24ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.73 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity88.63 m3·mol-1ChemAxon
Polarizability36.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9444
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7319
P-glycoprotein inhibitor INon-inhibitor0.857
P-glycoprotein inhibitor IINon-inhibitor0.8994
Renal organic cation transporterNon-inhibitor0.7685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.54
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9656
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9409
Ames testNon AMES toxic0.6229
CarcinogenicityNon-carcinogens0.7139
BiodegradationNot ready biodegradable0.8542
Rat acute toxicity1.8612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8546
hERG inhibition (predictor II)Inhibitor0.549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0006-0109000000-838e3fc396f400ef6f4bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0a4i-2901000000-15575a206ad43d931d6aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0a4i-3900000000-b83b6287d83301602f00View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0a6r-8900000000-5a447dc363e7b3d43351View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-004i-9200000000-0a29790b32c5ae5e192aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-004i-9000000000-32eb95f9c75cc8d8ee85View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-0006-0009000000-b451c07c9adbe534b75cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-01ox-0049000000-eaadc21e5bafdd34a66eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03di-0090000000-16b776d58e4e2dbc163eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-03di-0090000000-9fda88d7482dee887457View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-0009000000-338379e29df68a5396b7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0006-0209000000-d61c87359158078fa846View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-03di-2931000000-6a28d0dd33433a572e50View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-03di-4940000000-dcee56e4387108740566View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-03di-8960000000-9f1a7605079446735287View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-03e9-9620000000-c3bb475e828d5f8c88aaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomChemical entities
Super ClassOrganic compounds
ClassBenzenoids
Sub ClassBenzene and substituted derivatives
Direct ParentBenzenesulfonamides
Alternative ParentsBenzenesulfonyl compounds / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Organosulfonamides / N-alkylpyrrolidines / Aminosulfonyl compounds / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds
SubstituentsBenzenesulfonamide / Benzenesulfonyl group / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Organosulfonic acid amide / N-alkylpyrrolidine / Pyrrolidine
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorssulfonamide, benzamides, N-alkylpyrrolidine (CHEBI:32168 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Uniprot Name:
D(2) dopamine receptor
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Jaber M, Tison F, Fournier MC, Bloch B: Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res. 1994 Apr;23(1-2):14-20. [PubMed:7518029 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Uniprot Name:
D(3) dopamine receptor
Molecular Weight:
44224.335 Da
References
  1. Lipina TV, Vishnivetskaia GB: [Effect of sulpiride on immobility reflex and pinch-induced catalepsy in CBA/Lac male mice with various social status]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):482-7. [PubMed:19795811 ]
  2. Collo G, Zanetti S, Missale C, Spano P: Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci. 2008 Oct;28(7):1231-40. doi: 10.1111/j.1460-9568.2008.06423.x. [PubMed:18973551 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Uniprot Name:
Carbonic anhydrase 2
Molecular Weight:
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide.
Gene Name:
CA3
Uniprot ID:
P07451
Uniprot Name:
Carbonic anhydrase 3
Molecular Weight:
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Uniprot Name:
Cholinesterase
Molecular Weight:
68417.575 Da
References
  1. Vacca C, Maione S, Tozzi A, Marmo E: Benzamides and cholinesterases. Res Commun Chem Pathol Pharmacol. 1987 Feb;55(2):193-201. [PubMed:3823608 ]
  2. Dross K: [The relevance of anticholinesterase properties to toxicity and neuromuscular effects of sulpiride (author's transl)]. Arzneimittelforschung. 1977 Feb;27(2):404-6. [PubMed:577162 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:48